Arindam Bera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Arindam Bera has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anjan Bedi
Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
1 shared publication - Bibin Prasad
Solenic Medical, Inc., 4275 Kellway Circle, Suite 146, Addison, TX 75001, USA
1 shared publication - Kapil Dev Sayala
Southern Methodist University
1 shared publication - Krishnendu Maji
Department of Applied Chemistry, Maulana Abul Kalam Azad University of Technology, Nadia 741249, India
1 shared publication - Sanujit Patra
Department of Applied Chemistry, Maulana Abul Kalam Azad University of Technology, Nadia 741249, India
1 shared publication - Sarasija Das
Department of Chemistry, School of Advanced Sciences VIT‐AP University Amaravati, Andhra Pradesh India
1 shared publication
Latest Publications
- Open Access
- 30 November 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (12) , 1723
BODIPY-Based Molecules for Biomedical Applications
BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) derivatives have attracted attention as probes in applications like imaging and sensing due to their unique properties like (1) strong absorption and emission in the visible and near-infrared regions of the electromagnetic spectrum, (2) strong fluorescence and (3) supreme photostability. They have also been employed in areas like photodynamic therapy. Over the last decade, BODIPY-based molecules have even emerged as candidates for cancer treatments. Cancer remains a significant health issue world-wide, necessitating a continuing search for novel therapeutic options. BODIPY is a flexible fluorophore with distinct photophysical characteristics and is a fascinating drug development platform. This review provides a comprehensive overview of the most recent breakthroughs in BODIPY-based small molecules for cancer or disease detection and therapy, including their functional potential.
- 30 November 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (12) , 1723
Open AccessBODIPY-Based Molecules for Biomedical Applications
BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) derivatives have attracted attention as probes in applications like imaging and sensing due to their unique properties like (1) strong absorption and emission in the visible and near-infrared regions of the electromagnetic spectrum, (2) strong fluorescence and (3) supreme photostability. They have also been employed in areas like photodynamic therapy. Over the last decade, BODIPY-based molecules have even emerged as candidates for cancer treatments. Cancer remains a significant health issue world-wide, necessitating a continuing search for novel therapeutic options. BODIPY is a flexible fluorophore with distinct photophysical characteristics and is a fascinating drug development platform. This review provides a comprehensive overview of the most recent breakthroughs in BODIPY-based small molecules for cancer or disease detection and therapy, including their functional potential.